News

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025
Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented ...
pharmaphorum2d
Data at EULAR back Biogen, UCB's first-in-class lupus drug
Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...
Biogen (BIIB) Receives a Hold from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...
Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $115.00. The company’s shares ...
MedPage Today2d
First-in-Class Lupus Drug Aces Phase III Test
BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...
Barron's3d
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...